Overview: Ultrastructural Analysis TestIntroduction: The Ultrastructural Analysis Test examines tissue at a microscopic level to diagnose rare disorders or cancers, helping guide treatment for abnormal cell structures. Affecting 1 in 50,000 people with rare diseases, ultrastructural changes pose diagnostic challenges due to complexity. Following 2023 College of American Pathologists (CAP) guidelines, it uses electron microscopy for high accuracy, supporting histopathology screening. This test is vital for diagnosis, treatment planning, and improving outcomes in pathology.
Other Names: Tissue Ultrastructure Test, Electron Microscopy Assay.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic reliability.
Historical Milestone: Ultrastructural analysis began in the 1950s with research by Palade, who advanced electron microscopy. Improved resolution by JEOL enhanced detection, surpassing earlier light microscopy.
Purpose: Examines ultrastructural characteristics to diagnose rare disorders or cancers, guides targeted therapy, and evaluates patients with unexplained symptoms, aiming to manage disease.
Test Parameters: Ultrastructural characteristics
Pretest Condition: Tissue biopsy required. Collect tissue. Report history of cancer or rare disorders.
Specimen: Tissue (FFPE, 0.5-2 cma³); Tissue in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: 1 month
Medical History: Document cancer history or unexplained symptoms. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., metastasis), and sample collection risks.
Procedural Considerations: Uses electron microscopy to examine structures, requiring labs with specialized equipment. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Abnormal structures suggest rare disorders or cancer, guiding therapy. Early treatment might improve survival, while untreated cases lead to worsening. Normal structures may require other tests.
Specialist Consultation: Consult a pathologist for interpretation.
Additional Supporting Tests: Biopsy, genetic testing, or imaging to confirm diagnosis.
Test Limitations: Non-specific for cause; correlation with clinical status needed. False results possible with technical errors.
References: CAP Guidelines, 2023; Journal of Cell Biology, Palade GE, 2022.
